You have free access to this content

APLAR Journal of Rheumatology

Cover image for Vol. 9 Issue 2

August 2006

Volume 9, Issue 2

Pages 103–205

Currently known as: International Journal of Rheumatic Diseases

  1. Biologic therapies: the Asia-Pacific perspectives

    1. Top of page
    2. Biologic therapies: the Asia-Pacific perspectives
    3. Precautions and potential adverse effects of anti-tumour necrosis factor-α therapies
    4. Extended indications of anti-tumour necrosis factor-α therapy and other biologics for rheumatoid arthritis
    1. INTRODUCTION

      You have free access to this content
      Anti-tumour necrosis factor-α: the dawn of a new era in the treatment of rheumatoid arthritis (pages 103–104)

      Peter BROOKS, Ho-Youn KIM and C.S. LAU

      Version of Record online: 12 JUL 2006 | DOI: 10.1111/j.1479-8077.2006.00184.x

    2. You have free access to this content
      Biologicals: educational needs in APLAR countries (pages 105–106)

      Prakash K. PISPATI

      Version of Record online: 12 JUL 2006 | DOI: 10.1111/j.1479-8077.2006.00178.x

    3. You have free access to this content
      Infliximab (Remicade®): from bench to clinical practice. A paradigm shift in rheumatology practice (pages 107–118)

      Elizabeth C. HSIA, Kristin M. RULEY and Mahboob U. RAHMAN

      Version of Record online: 12 JUL 2006 | DOI: 10.1111/j.1479-8077.2006.00185.x

    4. ASIA-PACIFIC EXPERIENCE OF ANTI-TUMOUR NECROSIS FACTOR-α THERAPIES

      You have free access to this content
      Anti-tumor necrosis factor therapy: the Australian experience (pages 119–123)

      Peter NASH

      Version of Record online: 12 JUL 2006 | DOI: 10.1111/j.1479-8077.2006.197_1.x

      Corrected by:

      Corrigenda

      Vol. 9, Issue 3, 307, Version of Record online: 3 OCT 2006

    5. You have free access to this content
      A practical guide for the use of biologic agents in the treatment of rheumatoid arthritis* (pages 123–126)

      The Australian Rheumatology Association

      Version of Record online: 12 JUL 2006 | DOI: 10.1111/j.1479-8077.2006.197_2.x

    6. You have free access to this content
      Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a preliminary study from China (pages 127–130)

      Feng-Chun ZHANG, Yong HOU, Feng HUANG, Dong-Hai WU, Chun-De BAO, Li-Qing NI and Chen YAO

      Version of Record online: 12 JUL 2006 | DOI: 10.1111/j.1479-8077.2006.00186.x

    7. You have free access to this content
    8. You have free access to this content
    9. You have free access to this content
      The efficacy of infliximab for patients with rheumatoid arthritis in Japan: results of 5000 cases by post-marketing surveillance data (pages 142–145)

      Hiroshi OKA, Kusuki NISHIOKA, Masanori TOGO and Takahiro OCHI

      Version of Record online: 12 JUL 2006 | DOI: 10.1111/j.1479-8077.2006.00198.x

      Corrected by:

      Corrigenda

      Vol. 9, Issue 3, 307, Version of Record online: 3 OCT 2006

    10. You have free access to this content
      Clinical experience with tumor necrosis factor blockers in Korean rheumatoid arthritis patients (pages 146–149)

      Jin-Wuk HUR, Chan-Bum CHOI and Sang-Cheol BAE

      Version of Record online: 12 JUL 2006 | DOI: 10.1111/j.1479-8077.2006.00189.x

    11. You have free access to this content
      Clinical experience with infliximab among Filipino patients with rheumatic diseases (pages 150–156)

      Sandra V. NAVARRA, Anne-Annette RASO, Juan Javier LICHAUCO and Perry P. TAN

      Version of Record online: 12 JUL 2006 | DOI: 10.1111/j.1479-8077.2006.00190.x

    12. You have free access to this content
      The use of anti-tumour necrosis factor-α therapies for rheumatoid arthritis in Singapore (pages 157–160)

      B. Y. H. THONG, S. VASOO and E. T. KOH

      Version of Record online: 12 JUL 2006 | DOI: 10.1111/j.1479-8077.2006.00191.x

    13. You have free access to this content
      Experience of antitumor necrosis factor-α therapies in Taiwan (pages 161–164)

      WEI James Cheng-Chung, LAN Joung-Liang, CHEN Der-Yuan, CHOU Chung-Tei, CHOU Ming-Chih and J. TSAY Gregory

      Version of Record online: 12 JUL 2006 | DOI: 10.1111/j.1479-8077.2006.00179.x

  2. Precautions and potential adverse effects of anti-tumour necrosis factor-α therapies

    1. Top of page
    2. Biologic therapies: the Asia-Pacific perspectives
    3. Precautions and potential adverse effects of anti-tumour necrosis factor-α therapies
    4. Extended indications of anti-tumour necrosis factor-α therapy and other biologics for rheumatoid arthritis
    1. You have free access to this content
      Adverse effects of tumour necrosis factor-α blocking agents (pages 165–169)

      Kyung-Su PARK and Sung-Hwan PARK

      Version of Record online: 12 JUL 2006 | DOI: 10.1111/j.1479-8077.2006.00192.x

    2. You have free access to this content
      Risk of tuberculosis in a Chinese registry of rheumatoid arthritis and ankylosing spondylitis for tumour necrosis factor-α antagonists (pages 170–174)

      Feng HUANG, Lisha WANG, Jianglin ZHANG, Xiaohu DENG, Junhua GUO and Yamei ZHANG

      Version of Record online: 12 JUL 2006 | DOI: 10.1111/j.1479-8077.2006.00193.x

    3. You have free access to this content
    4. You have free access to this content
      Guidelines for tuberculosis prophylaxis during anti-tumour necrosis factor-α treatment: Indian Rheumatology Association (pages 181–183)

      R. HANDA, R. MISRA, V. P. CHATURVEDI, P. K. PISPATI, U. R. K. RAO, V. R. JOSHI and for the Indian Rheumatology Association

      Version of Record online: 12 JUL 2006 | DOI: 10.1111/j.1479-8077.2006.00181.x

    5. You have free access to this content
      Philippine guidelines on the screening for tuberculosis prior to the use of biologic agents (pages 184–192)

      Juan Javier T. LICHAUCO, Sandra A. TANKEH-TORRES, Sandra V. NAVARRA and Leonila F. DANS for the Task Force for TB Screening Prior to Use of Biologic Agents

      Version of Record online: 12 JUL 2006 | DOI: 10.1111/j.1479-8077.2006.00182.x

  3. Extended indications of anti-tumour necrosis factor-α therapy and other biologics for rheumatoid arthritis

    1. Top of page
    2. Biologic therapies: the Asia-Pacific perspectives
    3. Precautions and potential adverse effects of anti-tumour necrosis factor-α therapies
    4. Extended indications of anti-tumour necrosis factor-α therapy and other biologics for rheumatoid arthritis
    1. You have free access to this content
      Extended indications for anti-tumor necrosis factor-α therapy (pages 193–199)

      Chong-Hyeon YOON and Ho-Youn KIM

      Version of Record online: 12 JUL 2006 | DOI: 10.1111/j.1479-8077.2006.00195.x

    2. You have free access to this content

SEARCH

SEARCH BY CITATION